Why Is EyePoint (EYPT) Stock Down Today? A Trial Miss With An Asterisk

TL;DR

• EyePoint (EYPT) shares were down about 69% intraday Monday, from Friday's $14.75 close to $4.60 as of 2:11pm ET, with the market still open until 4pm. Market cap went from roughly $1.27bn to about $397m in a single session.
• The catalyst: DURAVYU missed the primary endpoint of the LUGANO Phase 3 wet AMD trial in the full 211-patient dataset. A post-hoc analysis excluding 9 patients (4%) whose vision loss was ruled unrelated to wet AMD found non-inferiority to on-label aflibercept, nominal p=0.0096.
• The secondary endpoints were genuinely strong: a 42% reduction in injection burden (p<0.0001), 54% of patients supplement-free through Week 56, and a favorable safety record with repeat dosing.
• Cantor Fitzgerald downgraded the stock to Neutral and pulled its price target. Mizuho called the readout "mixed" and warned that a second miss on the follow-up LUCIA trial, due in Q4 2026, "would be far more problematic."
• Rival Ocular Therapeutix (OCUL) rose on the news. Its competing drug axpaxli won its own Phase 3 trial outright in February 2026 and can go to the FDA without a second confirmatory study, which is exactly the position LUGANO's ambiguous result denies EyePoint.

The Board

A clean secondary-endpoint set sitting behind a primary endpoint that needed an exclusion to pass.

Why Is EyePoint Stock Down Today?

DURAVYU missed the primary endpoint of its LUGANO Phase 3 trial in wet age-related macular degeneration. The trial was built to show non-inferiority in best corrected visual acuity (BCVA) against on-label aflibercept (Regeneron and Bayer's Eylea) at weeks 52 and 56, and in the full 211-patient dataset that comparison did not clear the bar. Shares opened around $4.06 and traded as low as $3.95, a 16-month low, before recovering slightly to $4.60 by early afternoon, down 68.81% on the day per stockanalysis.com. Volume ran into the tens of millions of shares against a stock that normally trades a fraction of that. It's one of two biotech trial reactions moving stocks Monday: argenx cleared its own primary endpoint in a rarer disease the same morning, which is the mirror image of what happened here.

The Nine Patients That Changed The Answer

EyePoint's own explanation leans on a post-hoc cut of the data. Nine of the 211 patients, about 4%, lost 15 or more letters of vision for reasons the company says were unrelated to wet AMD. None of the patients on aflibercept had a comparable loss, which is itself unusual: historical trials put that failure rate at roughly 3-5% even on the control arm. Strip those nine patients out and DURAVYU clears non-inferiority, nominal p=0.0096.

That is a real statistical result. Mizuho's analysts called the exclusion "plausible" rather than dismissing it outright. But a trial's primary endpoint exists precisely so a company can't choose, after seeing the data, which patients get counted. Every biotech with a miss on its hands can find a subgroup that would have passed. The market's 69% reaction treats the full-dataset result as the real answer and the post-hoc fix as a footnote. I'd treat it the same way until LUCIA, the second pivotal trial, either backs up the aflibercept-comparable read or the primary miss repeats.

What Didn't Break

The part of this release that didn't get punished is the treatment-burden data, and it's worth separating from the endpoint fight. DURAVYU cut injection frequency by 42% against aflibercept with a p-value below 0.0001, a result the primary endpoint miss doesn't touch. 54% of patients stayed supplement-free through Week 56, and among those patients BCVA was non-inferior on its own (p=0.0035). Anatomic control, measured as central subfield thickness, came in within 4 microns of aflibercept at Week 56. Safety held up too: no excess cataracts, elevated eye pressure, inflammation, or insert migration versus the control arm.

None of that is nothing. A drug that needs roughly two fewer injections a year while holding vision and anatomy close to the standard of care is solving the actual problem sustained-release wet AMD drugs are chasing, which is that patients stop showing up for their aflibercept shots and lose vision from under-treatment. The issue is that the primary endpoint, the one regulators care about first, is the one that came with an asterisk.

EyePoint Isn't The Only One Chasing This

Options traders in this space have another name to watch. Ocular Therapeutix's competing tyrosine kinase inhibitor implant, axpaxli, won its own Phase 3 SOL-1 trial outright in February 2026, superiority against aflibercept at Week 36 (74.1% of axpaxli patients maintained vision against 55.8% on aflibercept, p=0.0006), no excluded patients, no post-hoc analysis required. Ocular Therapeutix is on track to file its NDA on that trial alone. OCUL shares rose more than 6% Monday. That move has nothing to do with new data of its own: EyePoint's stumble reads as evidence for the mechanism, TKI-based sustained delivery beating injection frequency, while handing the cleaner trial result to the competitor. Same subsector, same problem being solved, two very different afternoons.

Is EYPT A Buy?

The bull case rests on the cash and the secondary data. EyePoint had $180m in cash as of June 30, funding operations into Q4 2027 regardless of today's move, so this isn't a company that needs to raise capital into a crashed stock. The treatment-burden and safety data are real and would matter to prescribers even if LUCIA also comes in ambiguous, because reducing injection frequency is the entire commercial pitch for this drug class.

The bear case is that the market rarely rewards a saved endpoint. A primary endpoint miss that gets explained away by excluding patients is, at minimum, a credibility problem heading into LUCIA, and Mizuho's read that "a second miss would be far more problematic" is the correct framing. The FDA doesn't have to accept EyePoint's rationale for excluding those nine patients any more than it has to accept a clean trial with a manufacturing-site question attached, the exact bind Ultragenyx is in ahead of its own August 23 PDUFA date. With the stock down two-thirds in a session, the market has already priced in serious doubt about whether LUGANO's story survives contact with LUCIA.

I wouldn't buy this dip on the theory that the sell-off overreacted to a "technicality." The technicality is the whole disagreement between the company and the market, and betting on it requires the FDA to eventually agree that nine patients' vision loss really was unrelated to the disease being treated. I'd rather wait for LUCIA to either confirm or contradict that story before deciding which read was right.

The Options Angle

I don't have a live, sourced EYPT option chain for a session where the stock just moved 69% on 50-plus times average volume, and pricing a structure into that kind of dislocation off stale or unverifiable quotes would be worse than not pricing it at all. There's also no clean near-term catalyst to trade into: LUCIA doesn't top out until Q4 2026, months away, which is too far out and too binary an event for a defined-risk structure priced today to say much about where the stock lands by then. This is a name to watch into that October-ish readout, not one to price now. The pass gets logged the same way every play on this site does, in the Track Record ledger.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Conviction	Breakeven
1	Pass	Any directional options structure on today's move	N/A	Pricing not sourced this session	$4.60 (Aug 17, ~2:11pm ET, down 68.81% intraday) vs $14.75 Friday close	Not sourced	5/10	N/A

The One-Line Read

DURAVYU's secondary data still works. Its primary endpoint only works after nine patients get removed, and the market just decided that's not the same thing.